Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Multiple Allele Traits01:49

Multiple Allele Traits

34.7K
The Concept of Multiple Allelism
34.7K
Disorders of Erythrocytes01:27

Disorders of Erythrocytes

1.2K
Disorders of erythrocytes, or red blood cells (RBCs), include a range of conditions affecting their number, shape, or function.
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...
1.2K
iPS Cell Differentiation01:22

iPS Cell Differentiation

2.8K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
2.8K
Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

3.3K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.3K
Overview of Hematopoiesis01:20

Overview of Hematopoiesis

4.7K
Hematopoiesis, or blood cell production, is a vital biological process that begins early in embryonic development and continues throughout life. This process generates the various types of cells found in blood, including red blood cells, white blood cells, and platelets from hematopoietic stem cells (HSCs).
Developmental Phases of Hematopoiesis
Initially, HSCs are formed in the embryonic yolk sac, a critical site for early blood cell production. These stem cells subsequently migrate to other...
4.7K
Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

20
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
20

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Long-Term Complications of Sickle Cell Disease.

Pediatrics in review·2026
Same author

Moving on Up: Shifting Sickle Cell Disease Management During Adolescence in Preparation for Adulthood.

Pediatric blood & cancer·2026
Same author

Safety and effectiveness of voxelotor in individuals with sickle cell disease in the RETRO and PROSPECT US registries.

Blood advances·2026
Same author

ASH's commitment to SCD: building on 10 years of progress.

Blood advances·2025
Same author

Sickle cell disease: managing thromboembolism.

Hematology. American Society of Hematology. Education Program·2025
Same author

Metastatic Recurrence Among Adolescents and Young Adults With Cancer.

JAMA oncology·2025

関連する実験動画

Updated: Sep 5, 2025

A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy
07:24

A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy

1.8K

シックル 細胞 病 - 概要

Patricia L Kavanagh1, Titilope A Fasipe2, Ted Wun3

  • 1Division of General Pediatrics, Boston University School of Medicine, Boston Medical Center, Boston, Massachusetts.

JAMA
|July 5, 2022
PubMed
まとめ

シークル細胞病 (SCD) は 遺伝的に受け継がれる血液疾患で 10万人のアメリカ人が罹患しています 新しい治療法により,SCD患者の治療が改善され,ヒドロキシ尿素と幹細胞移植が補完されます.

さらに関連する動画

Characterization of Sickling During Controlled Automated Deoxygenation with Oxygen Gradient Ektacytometry
08:23

Characterization of Sickling During Controlled Automated Deoxygenation with Oxygen Gradient Ektacytometry

Published on: November 5, 2019

9.9K
Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
05:23

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload

Published on: March 14, 2017

19.6K

関連する実験動画

Last Updated: Sep 5, 2025

A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy
07:24

A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy

1.8K
Characterization of Sickling During Controlled Automated Deoxygenation with Oxygen Gradient Ektacytometry
08:23

Characterization of Sickling During Controlled Automated Deoxygenation with Oxygen Gradient Ektacytometry

Published on: November 5, 2019

9.9K
Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
05:23

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload

Published on: March 14, 2017

19.6K

科学分野:

  • 血液学
  • 遺伝学
  • 内科 医学

背景:

  • シクル細胞病 (Sickle cell disease,SCD) は,遺伝的に受け継がれるヘモグロビン疾患で,状の赤血球を発生させ,臓器の損傷を引き起こし,死亡率を増加させます.
  • 世界中で毎年30万人の乳児がSCDで生まれ,サハラ以南のアフリカ,インド,地中海,中東で顕著な流行があります.

研究 の 目的:

  • 状細胞疾患 (SCD) の診断,合併症,治療の進歩に関する現在の理解をレビューする.
  • 新しく承認された治療法や確立された介入を含む,SCDの治療状況の進化を強調する.

主な方法:

  • SCDの診断,臨床的表れ,治療結果に関する文献レビュー.
  • 新しいSCD治療法 (L-グルタミン,クリザンリズマブ,ヴォクセロター) と確立された治療法 (ヒドロキシ尿素,血芽細胞移植) の臨床試験データの分析.

主要な成果:

  • SCDは,新生児のスクリーニングまたは貧血と痛みの臨床プレゼンテーションで診断されます.
  • L-グルタミン,クリザンリズマブ,ヴォクセロータなどの新しい治療法は,入院,痛みの危機を軽減し,ヘモグロビンレベルを改善する効果を示しています.
  • ヒドロキシ尿素は第一線療法であり, 造血幹細胞移植は潜在的治療法ですが,ドナーの可用性によって制限されています.

結論:

  • SCDは寿命と生活の質に大きな影響を及ぼし,包括的な管理戦略を必要とします.
  • 最近の治療薬の承認により,SCDの患者にとって治療の選択肢が拡大され,改善された結果が得られました.
  • 血管新生幹細胞移植は 治療の唯一の選択肢であり 効果的で手頃な治療法に関する 研究を継続する必要性を強調しています